Intraventricular Administration of Etoposide in Brain Tumour Patients
Author Information
Author(s): Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U
Primary Institution: Department of Paediatric Haematology/Oncology, University of Bonn
Hypothesis
Is intraventricular administration of etoposide feasible for patients with metastatic brain tumours?
Conclusion
Intraventricularly administered etoposide is well tolerated and achieves significantly higher CSF peak levels compared to intravenous infusions.
Supporting Evidence
- Etoposide was administered daily via an indwelling subcutaneous reservoir for 5 consecutive days.
- Side effects included transient headache and bacterial meningitis during treatment.
- Pharmacokinetic analysis showed a terminal half-life of 7.4±1.2 hours.
Takeaway
Doctors tested a new way to give medicine to kids with brain tumours, and it worked well without causing too many problems.
Methodology
14 patients received intraventricular etoposide along with other chemotherapy, and CSF samples were analyzed for drug levels.
Limitations
The study had a small sample size and variability in drug clearance among patients.
Participant Demographics
Patients aged 2.1 to 33.2 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website